- Report
- January 2026
- 291 Pages
Global
From €2272EUR$2,500USD£1,953GBP
- Report
- September 2026
- 186 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 367 Pages
Global
From €5316EUR$5,850USD£4,569GBP
- Report
- May 2026
- 250 Pages
Global
From €4080EUR$4,490USD£3,507GBP
- Report
- May 2026
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 180 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 181 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 180 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 181 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 180 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- January 2026
- 185 Pages
Global
From €4089EUR$4,500USD£3,515GBP
- Report
- September 2026
- 185 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 196 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 189 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 193 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 189 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP
- Report
- September 2026
- 193 Pages
Global
From €3221EUR$3,545USD£2,769GBP
€3579EUR$3,939USD£3,077GBP

The Syndromic Multiplex Diagnostic market is a subset of the Diagnostics industry that focuses on the development and commercialization of multiplex assays. These assays are used to detect multiple biomarkers from a single sample, allowing for the simultaneous diagnosis of multiple diseases or conditions. Multiplex assays are used in a variety of clinical settings, including infectious disease, oncology, and autoimmune disease.
The Syndromic Multiplex Diagnostic market is driven by the increasing demand for rapid and accurate diagnosis of multiple diseases. This demand is driven by the need for improved patient outcomes, cost savings, and the ability to diagnose multiple diseases in a single test.
Some companies in the Syndromic Multiplex Diagnostic market include Abbott, Bio-Rad, Cepheid, Luminex, and Qiagen. Show Less Read more